Implant Sciences receives $5 million private financing:
This article was originally published in Clinica
Implant Sciences has completed a $5m private placement of common stock with four institutional investors. The Wakefield, Massachusetts company plans to use a portion of the proceeds for an accretive acquisition "which is currently under preliminary evaluation". Implant Sciences' product portfolio includes radioactive seeds for cancer treatment and coating technologies for medical devices, of which one is designed to modify the surface characteristics of orthopaedic joint implants so as to reduce polyethylene wear and prolong the implant's life.